RADNOR,
Pa., March 17, 2023 /PRNewswire/ -- NRx
Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx
Pharmaceuticals", the "Company"), a clinical-stage CNS
biopharmaceutical company, a Delaware Corporation, today announced
that it will release its fourth quarter and full year 2022
financial results after the market closes on Thursday, March 30, 2023, via press release,
which will be available on the Company's website at
https://ir.nrxpharma.com/. The Company will host a conference call
to discuss the financial results as well as provide a clinical and
corporate update at 4:30 p.m. ET the
same day.
A live webcast of the conference call will be available on the
Company's website
at https://ir.nrxpharma.com/news-events/ir-calendar. An
archive of the webcast will be available on the Company's
website.
Participants that are unable to join the webcast can access the
conference call via telephone by dialing domestically +1 (833)
630-1956 or internationally +1 (412) 317-1837.
About NRx Pharmaceuticals
Clinical-stage biopharmaceutical company developing therapeutics
for the treatment of central nervous system disorders, specifically
suicidal depression and post-traumatic stress disorder (PTSD). The
company's lead program NRX-101, an oral, fixed-dose combination of
D-cycloserine and lurasidone, targets the brain's NMDA receptor and
is being investigated in a Phase 3 trial under an FDA Special
Protocol Agreement and Breakthrough Therapy Designation in patients
with bipolar depression and suicidal ideation, an indication for
which the only approved treatment is electroshock therapy. NRx
Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute
Suicidality, a substantially broader indication. The Breakthrough
Therapy Designation and Special Protocol Agreement were awarded by
the FDA based on the Company's prior STABIL-B trial that
demonstrated substantial improvement over available therapy in
reducing depression and suicidality compared to placebo when
patients were treated with NRX-101 after a single dose of
ketamine.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-fourth-quarter-and-full-year-2022-financial-results-on-march-30-2023-301774809.html
SOURCE NRx Pharmaceuticals, Inc.